PROK Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 8.94%, SMA50 2.0%, SMA200 -0.11%). The stock’s 14-day RSI is 56.26 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.72% below its high and over 384.47% above its low. Average 10-day trading volume of 647.82 thousand shares is below the 3-month average of 890.48 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of 8.37% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.15. Next year's EPS is expected at -$11.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $12.00 to $1.00. The high target offers 610.06% upside. The low target suggests -40.83% downside. The mean target is $8.17. This offers 383.43% upside. ProKidney Corp. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by 16.67%. The prior quarter beat by -12.5%. Over the last six quarters, Apple has recorded several small beats. These include 21.43% in March 17, 2025.

ProKidney Corp. has 134.99 million shares outstanding. The public float is 86.72 million shares, elevated short interest at 9.02% of float. This equals 8.69 million shares. The short ratio is 1.69 days. Institutional investors hold 46.12% of the float. Insiders own 25.31%. Control Empresarial de Capitales S.A. de C.V. holds 73.84 million shares, Legorreta Pablo G. has 22.62 million shares and Cowen Aaron has 6.28 million shares.

ProKidney Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.76. This means the shares are trading above this model’s fair value.

ProKidney Corp. (NASDAQ:PROK) closed at $1.69 USD, gaining $0.02 (1.20%) from the previous close of $1.67. The stock is currently mid-range between its 52-week high and low $0.54 and $7.13. With a market capitalization of about $568.27 million, ProKidney Corp. is classified as a small-cap and shows higher-than-market volatility (beta ~1.70). Key stats such as the average daily volume over the past year has been around 951.70 thousand shares, volume is running light vs its 52-week average. Headquartered in Winston-Salem, NC, ProKidney Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bruce Culleton, the company employs approximately 204 people and listed since June 30, 2021. ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments.

ProKidney Corp. trades at a P/E ratio of -3.21, slightly below the S&P 500 average, with a price-to-sales ratio of 639.68 and a price-to-book ratio of -0.23 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.79, also above market averages.

ProKidney Corp. (NASDAQ:PROK) shares are flat -4.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ProKidney Corp. trading at a premium to the broader market with a P/E of -3.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.31, suggesting 569.23% upside. Our AI forecast model points to short-term weakness (-3.55% over two weeks), a medium-term rise (385.21% over three months), and a longer-term gain (33.14% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ProKidney Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.55%, with price expected at $1.63 by June 29, 2026, within a range of $1.54 to $1.71 3-Month Outlook: Projected rise of 385.21%, reaching $8.20 by September 11, 2026, with a range of $7.96 to $8.81. 1-Year Outlook: Projected gain of 33.14%, with price at $2.25 by June 15, 2027, within a range of $0.00 to $1.00.